Syon Capital LLC Purchases New Shares in Insulet Co. (NASDAQ:PODD)

Syon Capital LLC acquired a new position in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,326 shares of the medical instruments supplier’s stock, valued at approximately $288,000.

A number of other institutional investors also recently bought and sold shares of PODD. Wolff Wiese Magana LLC boosted its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares in the last quarter. Allworth Financial LP boosted its holdings in Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Lindbrook Capital LLC increased its position in Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the period. Finally, BluePath Capital Management LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at approximately $31,000.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.90% of the stock is currently owned by insiders.

Insulet Price Performance

Insulet stock opened at $166.19 on Friday. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The firm has a 50 day moving average price of $171.51 and a 200 day moving average price of $179.63. The company has a market cap of $11.64 billion, a price-to-earnings ratio of 57.11, a PEG ratio of 2.99 and a beta of 0.98.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 EPS. Sell-side analysts predict that Insulet Co. will post 3.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PODD. JPMorgan Chase & Co. upped their price objective on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Barclays lowered their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Piper Sandler reduced their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Finally, Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.